FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES IN	<b>BENEFICIAL</b>	<b>OWNERSHIP</b>

l	OMB APPRO	DVAL
	OMB Number:	3235-0287
l	Estimated average burd	len
	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Kaye Edward M. MD					2. Issuer Name and Ticker or Trading Symbol Sarepta Therapeutics, Inc. [ SRPT ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
					Sucpus Incrupeduco, inc. [ on i ]								X Dire		ctor	10%	Owner		
(Last) (First) (Middle)				3. D	Date of Earliest Transaction (Month/Dav/Year)							$\dashv$	X				er (specify w)		
215 FIRST STREET				04/	04/20/2017							President & CEO							
SUITE 415																			
				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
													Li	Line)					
IDGE M	A C	)2142											, , ,						
																	e tilali Olle K	eporting	
(S	tate) (.	Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date					Execution Dat ay/Year) if any		Date,	Transaction Disp Code (Instr. 5)		Disposed				4 and Sec Ben Owr		ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership	
								Code	v	Amount	() (I	A) or O)	Price		Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock 04/20/2				/2017	2017			F		4,349	(1) D \$32		\$32	2.54 66,820		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Security (Instr. 3)  Conversion or Exercise Price of Derivative Security  Date (Month/Day/Year)  Execution Date, if any (Month/Day/Year)		Code ((8)	ransaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			Amour or Numbe		ount mber	Deriv Secu	ative rity	derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
	Cdward M  (FI ST STREET  115  CIDGE M  (S  Security (Institute of perivative)  Price of Derivative	(First) ((ST STREET H15)  CIDGE MA (State) (Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle)  ST STREET  115  CIDGE MA 02142  (State) (Zip)  Table I - Note of the content o	(First) (Middle)  ST STREET  115  CIDGE MA 02142  (State) (Zip)  Table I - Non-Derive (Month/It)  Security (Instr. 3)  2. Transaction Date (Month/It)  Conversion or Exercise Price of Derivative (Month/Day/Year)  Price of Derivative (Month/Day/Year)  2. Table II - Derivate (e.g., pt. (Month/Day/Year) (Month/Day/Year)	(First) (Middle)  (First) (Middle)  ST STREET  (State) (Zip)  Table I - Non-Derivative  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Conversion or Exercise Price of Derivative  (Month/Day/Year)  (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)	(First) (Middle)  ST STREET  A. If American Structure Security (Instr. 3)  Table I - Non-Derivative Security (Instr. 3)  Table II - Derivative Security (Instr. 3)  Table II - Derivative Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Table II - Derivative Security (e.g., puts, calls of Derivative Security (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  Table II - Derivative Security (Instr. 3)  A. Deemed Execution Date, if any (Month/Day/Year)  Month/Day/Year)  Tansaction Code (Instr. 8)	(First) (Middle)  (First) (Middle)  ST STREET  (State) (Zip)  Table I - Non-Derivative Securities (Month/Day/Year)  (Stock 04/20/2017  Table II - Derivative Securities (e.g., puts, calls, warrance)  (Ronth/Day/Year) (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year)	Sarepta Therape  (First) (Middle)  (First) (Middle)  ST STREET  (State) (Zip)  Table I - Non-Derivative Securities Accurity (Instr. 3)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities Acque (e.g., puts, calls, warrants, and concerns of Derivative Security  (Month/Day/Year)  (Month/Day/Year)  Sarepta Therape  3. Date of Earliest Trans 04/20/2017  4. If Amendment, Date of Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  Sarepta Therape  3. Date of Earliest Trans 04/20/2017  4. If Amendment, Date of Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  Sarepta Therape	Sarepta Therapeutics, 3  3. Date of Earliest Transaction (Nou4/20/2017)  4. If Amendment, Date of Original Augusta (State)  Table I - Non-Derivative Securities Acquired (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired (Month/Day/Year)  Table II - Derivative Securities Acquired, Date (e.g., puts, calls, warrants, option (Month/Day/Year)  Table II - Derivative Securities Acquired (A) or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  Date	Sarepta Therapeutics, Inc.  Sarepta Therapeutics, Inc.  Sarepta Therapeutics, Inc.  3. Date of Earliest Transaction (Month/04/20/2017  4. If Amendment, Date of Original Filed  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Dissecurity (Instr. 3)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed (e.g., puts, calls, warrants, options, composition of Exercise Price of Derivative Security  Sarepta Therapeutics, Inc.  3. Date of Earliest Transaction (Month/04/20/2017)  4. If Amendment, Date of Original Filed  Execution Date, (Month/Day/Year)  Transaction Code (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Date  Date	Sarepta Therapeutics, Inc. [SRPT]  (First) (Middle)  ST STREET  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of (Month/Day/Year)  (Month/Day/Year)  Stock  Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, convertibe for Derivative Security  (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, convertibe Security  (Month/Day/Year)  A. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, convertibe Securities Acquired (A) or Disposed of (Month/Day/Year)  (Month/Day/Year)  Date Expiration  Date (Month/Day/Year)	Sarepta Therapeutics, Inc. [SRPT]  Sarepta Therapeutics, Inc. [SRPT]  3. Date of Earliest Transaction (Month/Day/Year) 04/20/2017  4. If Amendment, Date of Original Filed (Month/Day/Year) 4. If Amendment, Date of Original Filed (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warrants, options, convertible security Securities Acquired Date (e.g., puts, calls, warrants, options, convertible security (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Da	Sarepta Therapeutics, Inc. [SRPT]	Sarepta Therapeutics, Inc. [SRPT]   (Galaxies)   (Galax	Sarepta Therapeutics, Inc. [SRPT]   Check X X	Sarepta Therapeutics, Inc.   SRPT	Sarepta Therapeutics, Inc. [SRPT]   Check all applicable   X Director   X Officer (give title below)   Presider   X Form filed by More   X Form filed by Mo	Sarepta Therapeutics, Inc. [SRPT]   Check all applicable)   X Director   10%   X Direct	

## **Explanation of Responses:**

1. Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock.

## Remarks:

/s/David Tyronne Howton, as

Attorney-in-Fact for Edward

M. Kaye

\*\* Signature of Reporting Person

Date

04/24/2017

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.